Elder Pharmaceuticals Ltd. - Research Center
532322 ELDERPHARM Group (Z) BSE data
Add to watchlist
| Results |
Half yearly
|
| Statement | |
| More |
Half yearly results in brief
(Rs crore)
| Dec ' 14 | Dec ' 13 | Mar ' 13 | Sep ' 12 | Mar ' 12 | |
|---|---|---|---|---|---|
| Sales | 119.71 | 291.00 | 481.31 | 562.54 | 501.24 |
| Operating profit | -57.22 | 67.28 | 94.61 | 116.57 | 102.71 |
| Interest | 55.75 | 76.44 | 47.15 | 47.17 | 41.60 |
| Gross profit | -104.09 | -1.71 | 61.87 | 81.17 | 65.65 |
| EPS (Rs) | -58.39 | -8.07 | 18.46 | 23.79 | 19.40 |
Half yearly
results in details
| Dec ' 14 | Dec ' 13 | Mar ' 13 | Sep ' 12 | Mar ' 12 | |
|---|---|---|---|---|---|
| Other income | 8.88 | 7.45 | 14.40 | 11.78 | 4.53 |
| Stock adjustment | 3.60 | 25.42 | -40.54 | 64.97 | -20.68 |
| Raw material | 20.32 | 26.46 | 41.86 | 67.73 | 44.07 |
| Power and fuel | - | - | - | - | - |
| Employee expenses | 31.48 | 51.93 | 62.40 | 63.69 | 60.42 |
| Excise | - | - | - | - | - |
| Admin and selling expenses | - | - | - | - | - |
| Research and development expenses | - | - | - | - | - |
| Expenses capitalised | - | - | - | - | - |
| Other expenses | 121.53 | 119.91 | 322.98 | 249.58 | 314.72 |
| Provisions made | - | - | - | - | - |
| Depreciation | 15.82 | 14.86 | 14.21 | 14.97 | 12.28 |
| Taxation | - | - | 9.75 | 12.25 | 10.09 |
| Net profit / loss | -119.91 | -16.57 | 37.91 | 48.86 | 39.83 |
| Extra ordinary item | - | - | - | -5.09 | -3.44 |
| Prior year adjustments | - | - | - | - | - |
| Equity capital | 20.54 | 20.54 | 20.54 | 20.54 | 20.54 |
| Equity dividend rate | - | - | - | - | - |
| Agg.of non-prom. shares (Lacs) | - | 151.98 | 123.24 | 123.44 | 124.05 |
| Agg.of non promotoholding (%) | - | 74.00 | 60.01 | 60.10 | 60.40 |
| OPM (%) | -47.80 | 23.12 | 19.66 | 20.72 | 20.49 |
| GPM (%) | -80.95 | -.57 | 12.48 | 14.13 | 12.98 |
| NPM (%) | -93.25 | -5.55 | 7.65 | 8.51 | 7.88 |
© 2024 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis